Workflow
AbCellera Biologics(ABCL) - 2025 Q1 - Quarterly Results
ABCLAbCellera Biologics(ABCL)2025-05-08 20:14

Financial Performance - Total revenue for Q1 2025 was 4.2million,adecreasefrom4.2 million, a decrease from 10.0 million in Q1 2024[7] - Net loss for Q1 2025 was 45.6million,comparedtoanetlossof45.6 million, compared to a net loss of 40.6 million in Q1 2024, resulting in a loss per share of (0.15)[7][16]−NetlossforthethreemonthsendedMarch31,2024,was(0.15)[7][16] - Net loss for the three months ended March 31, 2024, was 40,610, compared to a net loss of 45,621 for the same period in 2025[19] Expenses - Research and Development (R&D) expenses increased to 42.5 million in Q1 2025 from 39.3millioninQ12024,reflectinga5.539.3 million in Q1 2024, reflecting a 5.5% growth in investments[7][16] - Sales and Marketing (S&M) expenses decreased to 2.8 million in Q1 2025 from 3.4 million in Q1 2024[7] - General & Administrative (G&A) expenses decreased to 16.2 million in Q1 2025 from 17.4millioninQ12024[7]−Cashusedinoperatingactivitieswas17.4 million in Q1 2024[7] - Cash used in operating activities was 41,708 for the three months ended March 31, 2024, significantly higher than 11,554in2025[19]−Stock−basedcompensationwas11,554 in 2025[19] - Stock-based compensation was 17,409 for the three months ended March 31, 2024, down from 14,786in2025[19]LiquidityandCashFlow−ThecompanyendedQ12025withover14,786 in 2025[19] Liquidity and Cash Flow - The company ended Q1 2025 with over 800 million in available liquidity, including 633millionincashandcashequivalents[2][7]−Cashandcashequivalentsandrestrictedcashattheendoftheperiodwere633 million in cash and cash equivalents[2][7] - Cash and cash equivalents and restricted cash at the end of the period were 150,862 for March 31, 2024, compared to 186,556forthesamedatein2025[19]−Totalcash,cashequivalents,andrestrictedcashshownonthebalancesheetwas186,556 for the same date in 2025[19] - Total cash, cash equivalents, and restricted cash shown on the balance sheet was 148,572 for March 31, 2024, versus 184,266forthesamedatein2025[19]−Netcashprovidedbyinvestingactivitieswas184,266 for the same date in 2025[19] - Net cash provided by investing activities was 29,910 for the three months ended March 31, 2024, compared to 7,935in2025[19]OperationalHighlights−Cumulativepartner−initiatedprogramstartswithdownstreamsreached97inQ12025,an87,935 in 2025[19] Operational Highlights - Cumulative partner-initiated program starts with downstreams reached 97 in Q1 2025, an 8% increase from 90 in Q1 2024[4] - The number of molecules that have reached the clinic increased to 16, representing a 23% growth from 13 in Q1 2024[4] - The company anticipates starting Phase 1 clinical trials for ABCL635 and ABCL575 in the second half of 2025[2] - AbCellera is focused on advancing its internal pipeline of first-in-class and best-in-class programs while collaborating on innovative drug development with partners[8] Changes in Financial Metrics - Purchases of property and equipment amounted to 24,140 for the three months ended March 31, 2024, compared to 10,636in2025[19]−Proceedsfrommarketablesecuritieswere10,636 in 2025[19] - Proceeds from marketable securities were 306,545 for the three months ended March 31, 2024, compared to 190,027in2025[19]−Researchfeesandgrantsreceivableshowedasignificantchangeof190,027 in 2025[19] - Research fees and grants receivable showed a significant change of (18,576) for the three months ended March 31, 2024, compared to (1,133)in2025[19]−Deferredrevenuechangedby(1,133) in 2025[19] - Deferred revenue changed by (8,017) for the three months ended March 31, 2024, while it increased by $13,313 in 2025[19]